On Target secures new FDA approval for Cytalux

By AuntMinnie.com staff writers

December 21, 2022 -- Molecular imaging agent developer On Target Laboratories has received U.S. Food and Drug Administration (FDA) approval for an expanded indication on its Cytalux (pafolacianine) optical imaging agent.

Previously approved in 2021 for intraoperative use in patients with ovarian cancer, Cytalux has now received approval for intraoperative identification of lung cancer lesions. The new indication will provide surgeons with the ability to integrate Cytalux into their treatment plan for adult patients with known or suspected lung cancer, according to the company.

Cytalux received a priority review designation by the FDA for the expanded indication.

Copyright © 2022 AuntMinnie.com
Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking